Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 23Colorectal Neoplasms 4Biliary Tract Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancoast Syndrome 1Neoplasms 1Locally Advanced Gastric or Gastroesophageal Junction Cancer 1Locally Advanced Gastric Adenocarcinoma 1Klatskin Tumor 1Hand-Foot Syndrome 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1Advanced Gastric Cancer 1Adenocarcinoma 1

Interventions

Gemcitabine 2Cisplatin 2Tegafur 1S 1 (combination) 1Drug Therapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Klatskin Tumor × S 1 (combination) × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡